Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyBiologicalProcess	actin filament-based process	CARMIL2 KCND3 ARHGEF5 CARMIL1 SYNE2 DVL2 OBSCN SRF TRIOBP TLE6 COBL MYO15A SHROOM2 PDLIM2 SYDE1	1.38e-06	912	78	15	GO:0030029
GeneOntologyBiologicalProcess	actin filament network formation	CARMIL2 CARMIL1 COBL	8.40e-06	11	78	3	GO:0051639
GeneOntologyBiologicalProcess	actin cytoskeleton organization	CARMIL2 ARHGEF5 CARMIL1 DVL2 OBSCN SRF TRIOBP TLE6 COBL MYO15A SHROOM2 PDLIM2 SYDE1	9.10e-06	803	78	13	GO:0030036
GeneOntologyBiologicalProcess	ectodermal placode morphogenesis	FRS2 GNAS NRG3	2.81e-05	16	78	3	GO:0071697
GeneOntologyBiologicalProcess	ectodermal placode formation	FRS2 GNAS NRG3	2.81e-05	16	78	3	GO:0060788
GeneOntologyBiologicalProcess	ectodermal placode development	FRS2 GNAS NRG3	4.08e-05	18	78	3	GO:0071696
GeneOntologyBiologicalProcess	negative regulation of actin filament depolymerization	CARMIL2 CARMIL1 TRIOBP SHROOM2	4.46e-05	52	78	4	GO:0030835
GeneOntologyBiologicalProcess	supramolecular fiber organization	MIA3 CARMIL2 ADAMTS7 ARHGEF5 CARMIL1 OBSCN SRF TRIOBP TLE6 COBL NCKAP5 MYO15A SHROOM2	5.70e-05	957	78	13	GO:0097435
GeneOntologyBiologicalProcess	regulation of actin filament depolymerization	CARMIL2 CARMIL1 TRIOBP SHROOM2	8.38e-05	61	78	4	GO:0030834
GeneOntologyBiologicalProcess	negative regulation of barbed-end actin filament capping	CARMIL2 CARMIL1	8.43e-05	4	78	2	GO:2000813
GeneOntologyBiologicalProcess	actin filament depolymerization	CARMIL2 CARMIL1 TRIOBP SHROOM2	1.14e-04	66	78	4	GO:0030042
GeneOntologyBiologicalProcess	actin filament organization	CARMIL2 ARHGEF5 CARMIL1 SRF TRIOBP TLE6 COBL MYO15A SHROOM2	1.27e-04	509	78	9	GO:0007015
GeneOntologyBiologicalProcess	gastrulation	CER1 ATOH8 DVL2 FRS2 SRF TNRC6C	1.52e-04	212	78	6	GO:0007369
GeneOntologyBiologicalProcess	barbed-end actin filament capping	CARMIL2 CARMIL1 TRIOBP	1.77e-04	29	78	3	GO:0051016
GeneOntologyBiologicalProcess	forebrain cell migration	AXL SYNE2 SRF NRG3	1.88e-04	75	78	4	GO:0021885
GeneOntologyBiologicalProcess	protein depolymerization	CARMIL2 CARMIL1 TRIOBP NCKAP5 SHROOM2	2.17e-04	144	78	5	GO:0051261
GeneOntologyBiologicalProcess	embryonic organ development	DVL2 FRS2 SRF TRIOBP COBL TNRC6C GNAS MYO15A SYDE1	2.63e-04	561	78	9	GO:0048568
GeneOntologyBiologicalProcess	regulation of barbed-end actin filament capping	CARMIL2 CARMIL1	2.93e-04	7	78	2	GO:2000812
GeneOntologyBiologicalProcess	cartilage development	CER1 MIA3 ADAMTS7 SRF GNAS MEX3C	3.18e-04	243	78	6	GO:0051216
GeneOntologyBiologicalProcess	embryonic morphogenesis	CER1 ATOH8 DVL2 FRS2 SRF TRIOBP COBL TNRC6C GNAS MYO15A	3.45e-04	713	78	10	GO:0048598
GeneOntologyBiologicalProcess	negative regulation of protein depolymerization	CARMIL2 CARMIL1 TRIOBP SHROOM2	3.62e-04	89	78	4	GO:1901880
GeneOntologyBiologicalProcess	regulation of cell projection organization	CUX2 CARMIL2 CARMIL1 SYNE2 MARK4 DVL2 SRF COBL CDHR5 ALK ARHGAP33	3.87e-04	863	78	11	GO:0031344
GeneOntologyBiologicalProcess	multicellular organismal-level homeostasis	GFI1B CARMIL2 AXL ARHGEF5 SRF ANKRD11 IRF4 GNAS USH2A ALK MEX3C TNFRSF4	5.20e-04	1043	78	12	GO:0048871
GeneOntologyBiologicalProcess	positive regulation of cell projection organization	CUX2 CARMIL2 CARMIL1 MARK4 DVL2 SRF COBL ALK	5.52e-04	494	78	8	GO:0031346
GeneOntologyBiologicalProcess	negative regulation of protein-containing complex disassembly	CARMIL2 CARMIL1 TRIOBP SHROOM2	5.64e-04	100	78	4	GO:0043242
GeneOntologyCellularComponent	actin cytoskeleton	PTPN12 CARMIL2 AXL ARHGEF5 CARMIL1 TRIOBP COBL MYO15A SHROOM2 PDLIM2 ARHGAP33	1.34e-05	576	81	11	GO:0015629
GeneOntologyCellularComponent	cell cortex	CABP1 DVL2 TLE6 COBL SHROOM2 PDLIM2 ARHGAP33	5.91e-04	371	81	7	GO:0005938
GeneOntologyCellularComponent	actin-based cell projection	FCRL3 SYNE2 TRIOBP CDHR5 MYO15A USH2A	7.38e-04	278	81	6	GO:0098858
GeneOntologyCellularComponent	pinosome	CARMIL2 CARMIL1	7.97e-04	11	81	2	GO:0044352
GeneOntologyCellularComponent	macropinosome	CARMIL2 CARMIL1	7.97e-04	11	81	2	GO:0044354
Domain	CARMIL_C	CARMIL2 CARMIL1	4.76e-05	3	75	2	IPR031943
Domain	CARMIL_C	CARMIL2 CARMIL1	4.76e-05	3	75	2	PF16000
Domain	SH3_2	MIA3 ARHGEF5 MYO15A ARHGAP33	3.97e-04	86	75	4	IPR011511
Domain	SH3_2	MIA3 ARHGEF5 MYO15A ARHGAP33	3.97e-04	86	75	4	PF07653
Domain	LRR_6	CARMIL2 CARMIL1 PPP1R37	1.40e-03	55	75	3	PF13516
Domain	SH3	MIA3 ARHGEF5 OBSCN MYO15A ARHGAP33	1.77e-03	216	75	5	SM00326
Domain	SH3	MIA3 ARHGEF5 OBSCN MYO15A ARHGAP33	1.77e-03	216	75	5	PS50002
Domain	SH3_domain	MIA3 ARHGEF5 OBSCN MYO15A ARHGAP33	1.92e-03	220	75	5	IPR001452
Domain	RhoGAP	ARHGAP23 SYDE1 ARHGAP33	1.98e-03	62	75	3	SM00324
Domain	RhoGAP	ARHGAP23 SYDE1 ARHGAP33	2.08e-03	63	75	3	PF00620
Domain	RHOGAP	ARHGAP23 SYDE1 ARHGAP33	2.17e-03	64	75	3	PS50238
Domain	RhoGAP_dom	ARHGAP23 SYDE1 ARHGAP33	2.17e-03	64	75	3	IPR000198
Domain	-	ARHGAP23 SYDE1 ARHGAP33	2.17e-03	64	75	3	1.10.555.10
Domain	PDZ	ARHGAP23 DVL2 SHROOM2 PDLIM2	2.50e-03	141	75	4	PF00595
Domain	IQ	OBSCN CEP131 MYO15A	2.92e-03	71	75	3	PF00612
Domain	PDZ	ARHGAP23 DVL2 SHROOM2 PDLIM2	2.98e-03	148	75	4	SM00228
Domain	-	ARHGAP23 DVL2 SHROOM2 PDLIM2	3.12e-03	150	75	4	2.30.42.10
Domain	PDZ	ARHGAP23 DVL2 SHROOM2 PDLIM2	3.20e-03	151	75	4	PS50106
Domain	PDZ	ARHGAP23 DVL2 SHROOM2 PDLIM2	3.27e-03	152	75	4	IPR001478
Domain	IQ	OBSCN CEP131 MYO15A	4.24e-03	81	75	3	SM00015
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	CARMIL2 ARHGEF5 CARMIL1 SYNE2 MARK4 ANKRD11 COBL CEP131 GNAS SRRM2 SYDE1 MEX3C PML	1.11e-07	861	82	13	36931259
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	SCAF1 CELSR3 ADAMTS7 MARK4 OBSCN ANKRD11 COBL CEP131 TNRC6C FBXL19 MED13L KIFC2 ARHGAP33 ANO8	2.89e-07	1105	82	14	35748872
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	BDP1 MIA3 KCND3 CARMIL1 RIN2 OBSCN SRF ANKRD11 TRIOBP COBL TNRC6C GNAS NRG3 SHROOM2 ANO8 CLBA1	3.39e-07	1489	82	16	28611215
Pubmed	T cell specific deletion of IRF4 with Ox40-Cre impairs effector and memory T cell responses in heart transplantation.	IRF4 TNFRSF4	5.49e-06	2	82	2	37211291
Pubmed	ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.	AXL ALK	5.49e-06	2	82	2	26616860
Pubmed	IRF4 is a novel mediator for neuronal survival in ischaemic stroke.	SRF IRF4	5.49e-06	2	82	2	24510125
Pubmed	Cell Migration and Invadopodia Formation Require a Membrane-binding Domain of CARMIL2.	CARMIL2 CARMIL1	1.64e-05	3	82	2	26578515
Pubmed	Cumulus cells of euploid versus whole chromosome 21 aneuploid embryos reveal differentially expressed genes.	DVL2 SRF	1.64e-05	3	82	2	34417138
Pubmed	PML-nuclear bodies are involved in cellular serum response.	SRF PML	1.64e-05	3	82	2	12622724
Pubmed	Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets.	SCAF1 RGL3 MCM9 SRRM2 SHROOM2 TSGA10IP	1.94e-05	233	82	6	37704626
Pubmed	Serum response factor is required for cortical axon growth but is dispensable for neurogenesis and neocortical lamination.	CUX2 NR4A2 SRF	2.16e-05	23	82	3	22090492
Pubmed	Epilepsy- and intellectual disability-associated CYFIP2 interacts with both actin regulators and RNA-binding proteins in the neonatal mouse forebrain.	MIA3 CARMIL2 TRIOBP COBL ARHGAP33	2.32e-05	143	82	5	32560809
Pubmed	High-throughput analyses of hnRNP H1 dissects its multi-functional aspect.	OGFR OBSCN SRF PPP1R37 CDHR5 FBXL19 HSF4 GNL1 PDLIM2 SYDE1 ANO8	2.76e-05	1021	82	11	26760575
Pubmed	Whirlin complexes with p55 at the stereocilia tip during hair cell development.	GNAS MYO15A	3.28e-05	4	82	2	16829577
Pubmed	Novel nuclear nesprin-2 variants tether active extracellular signal-regulated MAPK1 and MAPK2 at promyelocytic leukemia protein nuclear bodies and act to regulate smooth muscle cell proliferation.	SYNE2 PML	3.28e-05	4	82	2	19861416
Pubmed	FBXL19 recruits CDK-Mediator to CpG islands of developmental genes priming them for activation during lineage commitment.	FBXL19 MED13L	3.28e-05	4	82	2	29809150
Pubmed	Distinct roles for CARMIL isoforms in cell migration.	CARMIL2 CARMIL1	5.47e-05	5	82	2	19846667
Pubmed	Control of T helper 2 responses by transcription factor IRF4-dependent dendritic cells.	IRF4 TNFRSF4	8.19e-05	6	82	2	24076050
Pubmed	Inhibition of IRF4 in dendritic cells by PRR-independent and -dependent signals inhibit Th2 and promote Th17 responses.	IRF4 GNAS	8.19e-05	6	82	2	32014112
Pubmed	Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling.	AXL ALK	1.14e-04	7	82	2	19815557
Pubmed	FBXO32 links ubiquitination to epigenetic reprograming of melanoma cells.	OGFR CEP131 GNAS DDX24 GNL1	1.50e-04	212	82	5	33462405
Pubmed	Elongation factor 1 alpha1 and genes associated with Usher syndromes are downstream targets of GBX2.	MYO15A USH2A	1.96e-04	9	82	2	23144817
Pubmed	Expression of planar cell polarity genes during development of the mouse CNS.	CELSR3 DVL2	1.96e-04	9	82	2	16487141
Pubmed	Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.	CUX2 SYNE2 TRIOBP TNRC6C MED13L	1.97e-04	225	82	5	12168954
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	SCAF1 CHAF1B ARHGAP23 MARK4 DVL2 SRRM2 DDX24 PDLIM2 ARHGAP33 PML	2.93e-04	1116	82	10	31753913
Pubmed	Transcriptome analysis reveals transmembrane targets on transplantable midbrain dopamine progenitors.	KCND3 NR4A2	2.98e-04	11	82	2	25775569
Pubmed	FRS2α-mediated FGF signals suppress premature differentiation of cardiac stem cells through regulating autophagy activity.	FRS2 SRF	2.98e-04	11	82	2	22207710
Pubmed	Impact of cytosine methylation on DNA binding specificities of human transcription factors.	GFI1B CUX2 ZSCAN1 NR4A2 SRF IRF4 HSF4	3.05e-04	544	82	7	28473536
Pubmed	Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance.	CUX2 NR4A2	3.57e-04	12	82	2	25741722
Pubmed	The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2.	CARMIL2 CRACDL CARMIL1 FRS2 PPP1R37 COBL CDHR5	3.99e-04	569	82	7	30639242
Pubmed	Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine for Parkinson's disease.	CELSR3 DVL2 NR4A2	4.74e-04	64	82	3	24431302
Pubmed	Class III myosins shape the auditory hair bundles by limiting microvilli and stereocilia growth.	TRIOBP MYO15A	4.91e-04	14	82	2	26754646
Pubmed	Pellino-2 in nonimmune cells: novel interaction partners and intracellular localization.	PRR36 DVL2	4.91e-04	14	82	2	34674267
Pubmed	Image-based genome-wide siRNA screen identifies selective autophagy factors.	CHAF1B ADAMTS7 OBSCN MEX3C	5.58e-04	159	82	4	22020285
Pubmed	RGS12 polarizes the GPSM2-GNAI complex to organize and elongate stereocilia in sensory hair cells.	TRIOBP MYO15A	5.65e-04	15	82	2	36260679
Pubmed	SOX5 controls the sequential generation of distinct corticofugal neuron subtypes.	CUX2 NR4A2	5.65e-04	15	82	2	18215621
Pubmed	Satb2 is a postmitotic determinant for upper-layer neuron specification in the neocortex.	CUX2 NR4A2	5.65e-04	15	82	2	18255031
Pubmed	Frs2α enhances fibroblast growth factor-mediated survival and differentiation in lens development.	FRS2 ALK	7.30e-04	17	82	2	23136392
Pubmed	The docking protein FRS2alpha is an essential component of multiple fibroblast growth factor responses during early mouse development.	CER1 FRS2	8.20e-04	18	82	2	15870281
Pubmed	The role of α-E-catenin in cerebral cortex development: radial glia specific effect on neuronal migration.	CUX2 NR4A2	1.01e-03	20	82	2	25147501
Pubmed	Charting the landscape of tandem BRCT domain-mediated protein interactions.	CARMIL2 NOM1 WBP1L SRRM2 DDX24 USH2A PML	1.04e-03	670	82	7	22990118
Pubmed	A comprehensive resource of interacting protein regions for refining human transcription factor networks.	CABP1 NOM1 NR4A2 GNAS	1.10e-03	191	82	4	20195357
Pubmed	Chato, a KRAB zinc-finger protein, regulates convergent extension in the mouse embryo.	CER1 DVL2	1.12e-03	21	82	2	18701545
Pubmed	Promyelocytic leukemia protein interacts with the apoptosis-associated speck-like protein to limit inflammasome activation.	CEP131 PML	1.12e-03	21	82	2	24407287
Pubmed	Genome-wide YFP fluorescence complementation screen identifies new regulators for telomere signaling in human cells.	OGFR DDX24 REM2 PDLIM2 PML	1.12e-03	330	82	5	21044950
Pubmed	FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia.	BDP1 CARMIL1 OBSCN ANKRD11 COBL DDX24	1.16e-03	497	82	6	36774506
Pubmed	microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart.	NELFA SRF	1.23e-03	22	82	2	19015276
Pubmed	Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers.	PIK3AP1 CEP131 NRG3 USH2A	1.28e-03	199	82	4	23382691
Pubmed	Systematic protein-protein interaction mapping for clinically relevant human GPCRs.	SCAF1 PRR36 NELFA OGFR MARK4 GNAS ANO8	1.31e-03	697	82	7	28298427
Pubmed	A forward genetic screen reveals roles for Nfkbid, Zeb1, and Ruvbl2 in humoral immunity.	PIK3AP1 IRF4	1.35e-03	23	82	2	22761313
Pubmed	Embryonic lethality in mice lacking Trim59 due to impaired gastrulation development.	CER1 TRIOBP	1.35e-03	23	82	2	29467473
Pubmed	Interactomes of Glycogen Synthase Kinase-3 Isoforms.	MIA3 PTPN12 COBL CEP131	1.54e-03	209	82	4	36779422
Pubmed	The Maternal Microbiome Programs the m6A Epitranscriptome of the Mouse Fetal Brain and Intestine.	CABP1 COBL	1.59e-03	25	82	2	35874829
Pubmed	ZFP57 dictates allelic expression switch of target imprinted genes.	COBL GNAS	1.59e-03	25	82	2	33500348
Pubmed	MKRN2 Physically Interacts with GLE1 to Regulate mRNA Export and Zebrafish Retinal Development.	SCAF1 SYNE2 SRRM2 DDX24 MEX3C	1.60e-03	358	82	5	32460013
Pubmed	Prediction of the coding sequences of unidentified human genes. XVIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.	OBSCN TNRC6C ANO8	1.78e-03	101	82	3	10997877
Pubmed	The TRIM9/TRIM67 neuronal interactome reveals novel activators of morphogenesis.	DVL2 CEP131 TNRC6C ARHGAP33	1.79e-03	218	82	4	33378226
Pubmed	Selected reaction monitoring mass spectrometry reveals the dynamics of signaling through the GRB2 adaptor.	PIK3AP1 PTPN12 FRS2	1.89e-03	103	82	3	21706016
Pubmed	The T-box transcription factor Eomes/Tbr2 regulates neurogenesis in the cortical subventricular zone.	CUX2 NR4A2	1.99e-03	28	82	2	18794345
Pubmed	Proteins recruited by SH3 domains of Ruk/CIN85 adaptor identified by LC-MS/MS.	CARMIL1 SRRM2 SYDE1	2.16e-03	108	82	3	19531213
GeneFamily	PDZ domain containing	ARHGAP23 DVL2 SHROOM2 PDLIM2	7.01e-04	152	48	4	1220
GeneFamily	Receptor Tyrosine Kinases\|CD molecules	AXL ALK	5.05e-03	40	48	2	321
GeneFamily	Rho GTPase activating proteins\|BCH domain containing	ARHGAP23 ARHGAP33	7.80e-03	50	48	2	721
GeneFamily	Fibronectin type III domain containing	AXL OBSCN USH2A	8.79e-03	160	48	3	555
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	ARHGEF5 OBSCN	1.33e-02	66	48	2	722
ToppCell	mild\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	BDP1 SYNE2 ANKRD11 MED13L SRRM2 DDX24	1.89e-06	200	82	6	12f1685ce8f218433068e090c9d839cd5a1910bf
ToppCell	COVID-19\|World / Disease, condition lineage and cell class	SYNE2 ANKRD11 GNAS MED13L SRRM2 DDX24	1.89e-06	200	82	6	7dec470c379cd89f05a0f37c8628b21f136e52f0
ToppCell	droplet-Lung-18m-Hematologic-myeloid-classical_monocyte-classical_monocyte_l15\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	PIK3AP1 AXL CRACDL SIMC1 NR4A2	2.23e-06	114	82	5	84318a25a701331ccd5e68221239c543b9c0cc54
ToppCell	10x5'-Liver-Lymphocytic_Invariant-Inducer-like-ILC3\|Liver / Manually curated celltypes from each tissue	CRACDL NCKAP5 SHROOM2 REM2 TNFRSF4	1.28e-05	163	82	5	7f61483eeb1fde21843c6391468e13cb0cc2a89f
ToppCell	368C-Lymphocytic-NK_cells-NK_cell_E\|368C / Donor, Lineage, Cell class and subclass (all cells)	CRACDL DVL2 KIFC2 MEX3C TNFRSF4	1.52e-05	169	82	5	0d96c0b4fd26fbc0bf44ff7bed2936eebcc55b74
ToppCell	3'-Adult-SmallIntestine-Endothelial-blood_vessel_EC-arterial_capillary\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CABP1 ADAMTS7 ATOH8 CRACDL TNFRSF4	2.06e-05	180	82	5	efc4c5a4dea456527526bbfd88cf70d803893671
ToppCell	droplet-Marrow-BM\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	OGFR ANKRD11 PPP1R37 GNAS PML	2.12e-05	181	82	5	4169a1527b9c8f5783b8cc44e3a3924f8ed9a5e2
ToppCell	LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ATOH8 RGL3 SYNE2 COBL KIFC2	2.29e-05	184	82	5	42ce855b4f8475a8298192feec785bdc69bc5bb0
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ATOH8 RGL3 CARMIL1 COBL KIFC2	2.41e-05	186	82	5	3aebe163799109ffc67e4e10ee47c2dd0886a92c
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	CABP1 SYNE2 COBL CDHR5 NCKAP5	2.41e-05	186	82	5	b1edc341d6684b347dc9e21b34f62f51d095d735
ToppCell	droplet-Bladder-nan\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SYNE2 NR4A2 ANKRD11 SRRM2 DDX24	2.48e-05	187	82	5	663991a8afe652e92363b64bcbd68c14d0307f0e
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ATOH8 RGL3 SYNE2 COBL KIFC2	2.48e-05	187	82	5	58d48128547ee3513d0bf7f78e61b76b1c472ca9
ToppCell	IPF-Endothelial-VE_Capillary_A\|IPF / Disease state, Lineage and Cell class	RIN2 NCKAP5 NRG3 SHROOM2 TNFRSF4	2.67e-05	190	82	5	b4e35cbfe4d43d2cd51f29c3085e4d9b1012e6f0
ToppCell	RV-10._Endothelium_II\|World / Chamber and Cluster_Paper	PTPN12 RIN2 SYNE2 NRG3 SHROOM2	2.88e-05	193	82	5	2531266bc57339d4e2b22a88817008e32b8c1598
ToppCell	RV-09._Endothelium_I\|RV / Chamber and Cluster_Paper	CABP1 ATOH8 CRACDL RIN2 SYNE2	2.95e-05	194	82	5	7b408096e717f2327c12aea35a8d5fc4621d3b06
ToppCell	10x3'2.3-week_17-19\|World / cell types per 3 fetal stages;per 3',per 5'	ANKRD11 IRF4 GNAS SRRM2 MEX3C	3.18e-05	197	82	5	f5cfad0b42d0f817e22cc78b9bfb2b4b7e4330ed
ToppCell	Tracheal-NucSeq-Immune_Myeloid-Dendritic_cell-DC_activated\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	CABP1 IRF4 ARHGAP33 MEX3C TNFRSF4	3.33e-05	199	82	5	6dc446a5d183b01bdf227e45bd88d0b3d8b1c56a
ToppCell	LPS_IL1RA-Hematopoietic_Myeloid-Dendritic_cells-pDC\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	CUX2 NR4A2 IRF4 CDHR5 TSGA10IP	3.33e-05	199	82	5	f197ab861767ee06aa47b86c537fb3d8c2b2bc3e
ToppCell	LPS_anti-TNF-Hematopoietic_Myeloid-Dendritic_cells-pDC\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	CUX2 CARMIL2 CRACDL NR4A2 TSGA10IP	3.41e-05	200	82	5	6a34e07e6d77fe3fdd9ff44c4b1e46a023f6d6a2
ToppCell	Tracheal-NucSeq-Epithelial-Epi_submucosal-gland-SMG_Serous\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	PIK3AP1 CRACDL COBL GNAS NRG3	3.41e-05	200	82	5	7c2d499af60654b7b28f172ac2c914ad49fb74b4
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L6_IT-L6_IT_ALM_Oprk1\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	CER1 IQANK1 USH2A	8.93e-05	47	82	3	b83e9a0f8db3f1581c5621f9d835ae2423ba0978
ToppCell	LPS-antiTNF-Myeloid-Dendritic_cells-pDC\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CUX2 CRACDL IRF4 TSGA10IP	9.49e-05	129	82	4	454bae525f6db3d0dd6347d2a2c3ea9dda9cd212
ToppCell	MS-CD4-CD4_Treg\|MS / Condition, Cell_class and T cell subcluster	ARHGAP23 REM2 ANO8 TNFRSF4	1.34e-04	141	82	4	df257dd4dcc45c1ace57340798e150a6e932531d
ToppCell	(2)_NK/T-(23)_CD4+_T_cell-(230)_CD4+/CD25+_Reg_T_cell\|(23)_CD4+_T_cell / immune cells in Peripheral Blood (logTPM normalization)	FCRL3 SYNE2 IRF4 TNFRSF4	1.88e-04	154	82	4	059bdf6843f94f5028d4df6aa025865a9edb4521
ToppCell	356C-Lymphocytic-CD4_T-cell-Treg_cell_4\|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)	FCRL3 CELSR3 ARHGAP23 TRIOBP	1.88e-04	154	82	4	1f8d127b657976656e4ec292f26d619943533b86
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Glomerular_Capillary_Endothelial_Cell_prolif\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CHAF1B ADAMTS7 NRG3 TNFRSF4	1.92e-04	155	82	4	5d157478669b609e1f0f0a75afd0112571fc2c46
ToppCell	Bac-SEP-Lymphocyte-T_NK-CD4_TEM\|Bac-SEP / Disease, Lineage and Cell Type	KCND3 SYNE2 TNRC6C MIR9-1HG	1.97e-04	156	82	4	ef6bad99bcb30956863cd490c613e251f3b27ba0
ToppCell	356C-Myeloid-Dendritic-pDC\|356C / Donor, Lineage, Cell class and subclass (all cells)	COBL IRF4 REM2 KIFC2	1.97e-04	156	82	4	d9d87368e43b24952e70f31f38425e15b716ff5b
ToppCell	367C-Lymphocytic-CD4_T-cell-Treg_cell_3\|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)	ARHGAP23 ATOH8 FAM110D TNFRSF4	2.02e-04	157	82	4	6a0aa66964eecbbc232abf1d2e6c8422e4ce69d0
ToppCell	TCGA-Bladder-Primary_Tumor-Urothelial_Carcinoma-Papillary_Muscle_Invasive_Urothelial_Carcinoma\|TCGA-Bladder / Sample_Type by Project: Shred V9	ATOH8 RGL3 PPP1R37 KIFC2	2.07e-04	158	82	4	dc559503bab3ec1b9ea54ef2e896d1be33e5344c
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Glomerular_Capillary_Endothelial_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGAP23 RIN2 NRG3 TNFRSF4	2.12e-04	159	82	4	d3f81ba22160568ccaa6d2b04ebfd30630f9a6db
ToppCell	VE-mono3\|VE / Condition, Cell_class and T cell subcluster	AXL RGL3 RIN2 NR4A2	2.22e-04	161	82	4	7df3fefc55ab43b897fc78d1f0c7383b10ac33d5
ToppCell	367C-Lymphocytic-CD4_T-cell-Treg_cell_3\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	ARHGAP23 ATOH8 FAM110D TNFRSF4	2.22e-04	161	82	4	22fea192cd5f6d3544533d8b10e1d74dfedf0f05
ToppCell	VE-mono3-\|VE / Condition, Cell_class and T cell subcluster	AXL RGL3 RIN2 NR4A2	2.22e-04	161	82	4	4e45bf7eceb0ee30dec4d8852778366776ea5a8f
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c12-FOXP3\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	SYNE2 NRG3 ANO8 TNFRSF4	2.33e-04	163	82	4	4dfd408aa700e307478ee35f6b902f68719d8d9e
ToppCell	droplet-Liver-LIVER-NPC-1m-Lymphocytic-Kupffer_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UBXN11 LYSMD2 HSF4 ANO8	2.44e-04	165	82	4	8c7a6f9e2ca0ce077426d3d0726e3f5a4c03b296
ToppCell	NS-critical-d_07-13-Myeloid-pDC\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	CABP1 CUX2 IRF4 CDHR5	2.44e-04	165	82	4	17d5c4a111d9b5400780bc5e7b93ce2f5d69ceb7
ToppCell	Influenza_Severe-pDC\|World / Disease group and Cell class	CUX2 CRACDL IRF4 CDHR5	2.50e-04	166	82	4	bd25ce4c03c3d6cd9d986b9be1d355da52f0f2d7
ToppCell	367C-Lymphocytic-NK_cells-NK_cell_D3\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	PIK3AP1 GFI1B NR4A2 SHROOM2	2.56e-04	167	82	4	99db8871c62336bd215efb65e969783d2b6003b0
ToppCell	mild_COVID-19_(asymptomatic)-pDC\|World / disease group, cell group and cell class (v2)	CUX2 KCND3 AXL IRF4	2.56e-04	167	82	4	bf08f17965a4dd03f371b4ed0ab0d5e62ed61307
ToppCell	Adult-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D231\|Adult / Lineage, Cell type, age group and donor	CELSR3 ARHGAP23 OBSCN NRG3	2.56e-04	167	82	4	5af9127bae05768a5164d5708a4ad37edca99324
ToppCell	10x5'-lymph-node_spleen-Myeloid_Dendritic-pDC\|lymph-node_spleen / Manually curated celltypes from each tissue	CUX2 COBL CDHR5 SHROOM2	2.61e-04	168	82	4	cfed36fece51871a5abbcde71f6bd5e7212357ff
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-Degenerative_Endothelial_Cell-Degenerative_Peritubular_Capilary_Endothelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	CER1 FAM110D MN1 TNFRSF4	2.67e-04	169	82	4	db71386408053171363fa8411f5a36c2192487e0
ToppCell	356C-Epithelial_cells-Epithelial-E_(AT2)-\|356C / Donor, Lineage, Cell class and subclass (all cells)	ZSCAN1 ATOH8 RGL3 SHROOM2	2.74e-04	170	82	4	4cd3b7e43a061948084c01713ae141b5c2c07d89
ToppCell	356C-Epithelial_cells-Epithelial-E_(AT2)\|356C / Donor, Lineage, Cell class and subclass (all cells)	ZSCAN1 ATOH8 RGL3 SHROOM2	2.74e-04	170	82	4	36c9f7f98612a72dc511c8da4358d67444f6bcf4
ToppCell	3'-Broncho-tracheal-Immune_Myeloid-Dendritic-plasmacytoid_dendritic_cell-Plasmacytoid_DCs-Plasmacytoid_DCs_L.1.5.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CUX2 ANKRD11 IRF4 CDHR5	2.80e-04	171	82	4	4fd2c7977c512c51507f055fc74b111c0228ed8b
ToppCell	Adult-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D122\|Adult / Lineage, Cell type, age group and donor	FAM110D OBSCN NRG3 SHROOM2	2.80e-04	171	82	4	bd20e85d36fa9d7ddc8afef6a1dea75efc9ee1dc
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c12-FOXP3\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	GDF5-AS1 CELSR3 SYNE2 TNFRSF4	2.86e-04	172	82	4	eee45759284baa3ed77da6a5fbcc4f8f6c553106
ToppCell	Immune_cells-pro-B\|World / Lineage and Cell class	ADAMTS7 CRACDL IRF4 REM2	2.99e-04	174	82	4	e173adbf5789dfa20f3cbc668efde5f0992ac219
ToppCell	droplet-Lung-1m-Hematologic-lymphocytic-regulatory_T_cell-regulatory_T_cell\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CHAF1B UBXN11 HSF4 TNFRSF4	2.99e-04	174	82	4	33386750842c47ad7e7286d0f26a556da1a2de02
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Neuronal-neurons_B-Branch_B1_(eMN)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SRF CEP131 MYO15A REM2	2.99e-04	174	82	4	271c51d220842402975d97c86c9acfdbdf62a32c
ToppCell	droplet-Lung-1m-Hematologic-lymphocytic-regulatory_T_cell\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CHAF1B UBXN11 HSF4 TNFRSF4	2.99e-04	174	82	4	9344d4e76d7d9429aea87d3c0b98246200d16014
ToppCell	metastatic_Brain-T/NK_cells-Exhausted_Tfh\|metastatic_Brain / Location, Cell class and cell subclass	UBXN11 MARK4 IRF4 TNFRSF4	3.05e-04	175	82	4	b732c6a423c28856211002107d8c611dcfb6f265
ToppCell	normal_Lymph_Node-B_lymphocytes-GrB-secreting_B_cells\|normal_Lymph_Node / Location, Cell class and cell subclass	CUX2 COBL CDHR5 MED13L	3.05e-04	175	82	4	29fbdfe1d3bfcb063be2bced0128a33176c5b78f
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Immune-Myeloid-Macrophage_Dendritic-Plasmacytoid_Dendritic_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	PIK3AP1 CUX2 CARMIL2 IRF4	3.12e-04	176	82	4	8488997e0f02e874f53fae1690da63e0dd1d0780
ToppCell	TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Colon_Adenocarcinoma-2\|TCGA-Colorectal / Sample_Type by Project: Shred V9	PIK3AP1 LYSMD2 TLE6 PML	3.12e-04	176	82	4	1870860a9ebe7a655c4ea8898427e1097ee23113
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_A_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NR4A2 SRF GNAS REM2	3.19e-04	177	82	4	1dc69c661e70e7e22bd9d7cf953eb638da9fd43c
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_A_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NR4A2 SRF GNAS REM2	3.19e-04	177	82	4	426a9845df7fd13b02e744532c336c60bc4d4a22
ToppCell	Control-Epithelial_alveolar-AT_1-Differentiating_AT1\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ATOH8 CARMIL1 COBL KIFC2	3.19e-04	177	82	4	9af14a056eb6d88c6f11b09f6d4c0d3448d647d5
ToppCell	droplet-Fat-BAT+GAT+MAT-30m-Epithelial\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CUX2 CDHR5 MYO15A VWCE	3.26e-04	178	82	4	58857bb8c13e0e1c6d9f5c1258f00fff62063d68
ToppCell	droplet-Fat-BAT+GAT+MAT-30m-Epithelial-nan\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CUX2 CDHR5 MYO15A VWCE	3.26e-04	178	82	4	8b7df6ab8709d9ab9dff97677cc4561aec2745bc
ToppCell	droplet-Fat-BAT+GAT+MAT-30m-Epithelial-epithelial_cell\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CUX2 CDHR5 MYO15A VWCE	3.26e-04	178	82	4	b0baf5667e3301898b3e45e974b8a8530af6a338
ToppCell	3'-Distal_airway-Immune_Myeloid-Dendritic-plasmacytoid_dendritic_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CUX2 CARMIL2 IRF4 CDHR5	3.33e-04	179	82	4	4808469096cd6bec2bdfcf4fc55aa324757600c3
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ATOH8 RGL3 COBL KIFC2	3.33e-04	179	82	4	04ce3673e46606f63d9c87bcba3a64c96817d812
ToppCell	3'-Distal_airway-Immune_Myeloid-Dendritic-plasmacytoid_dendritic_cell-Plasmacytoid_DCs\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CUX2 CARMIL2 IRF4 CDHR5	3.33e-04	179	82	4	4d55718c6afd8a038d93cc77b9b08171dab9976f
ToppCell	3'-Distal_airway-Immune_Myeloid-Dendritic-plasmacytoid_dendritic_cell-Plasmacytoid_DCs-Plasmacytoid_DCs_L.1.5.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CUX2 CARMIL2 IRF4 CDHR5	3.40e-04	180	82	4	6a2366d76276452141db1bd93013a9503525f574
ToppCell	mild-Myeloid-pDC\|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	CUX2 AXL COBL IRF4	3.40e-04	180	82	4	38614155fa537d0defda914c531c697be0ef06d8
ToppCell	(2)_NK/T-(230)_CD4+/CD25+_Reg_T_cell\|(2)_NK/T / immune cells in Peripheral Blood (logTPM normalization)	FCRL3 ARHGAP23 IRF4 TNFRSF4	3.47e-04	181	82	4	ad14c7111d4fb924afd233cb114447f195373a7c
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ATOH8 RGL3 COBL KIFC2	3.47e-04	181	82	4	b45b11428d13950369347e051d4d517efb2bd4fd
ToppCell	COVID-19-Endothelial_cells-Capillary_endothelial_cells\|COVID-19 / group, cell type (main and fine annotations)	SYNE2 NCKAP5 NRG3 SHROOM2	3.47e-04	181	82	4	c5f9c92af1384d9089c65afdf41c6feb8345a3ae
ToppCell	droplet-Kidney-KIDNEY-30m-Epithelial-collecting_duct_principal_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CUX2 INSYN1 KCND3 TLE6	3.47e-04	181	82	4	7af469f5bcb9b1ab3f35b2758bf2afb87e8eba57
ToppCell	metastatic_Lymph_Node-Myeloid_cells-pDCs\|Myeloid_cells / Location, Cell class and cell subclass	CUX2 COBL IRF4 CDHR5	3.54e-04	182	82	4	02e04294fce12591c32d7bd0e866a000ad1f836e
ToppCell	COVID-19_Mild-gd_T\|COVID-19_Mild / Disease condition and Cell class	PIK3AP1 FCRL3 SYNE2 MIR9-1HG	3.62e-04	183	82	4	f593a89b0aa8fffdfa403769916facfd30358521
ToppCell	normal_Lung-B_lymphocytes-GrB-secreting_B_cells\|normal_Lung / Location, Cell class and cell subclass	CUX2 ANKRD11 IRF4 CDHR5	3.62e-04	183	82	4	c930b957d16f9b0904b6c424acd914532e5cc137
ToppCell	15-Distal-Immune-Hematopoietic,_B_Cells\|Distal / Age, Tissue, Lineage and Cell class	PIK3AP1 GFI1B CARMIL2 IRF4	3.69e-04	184	82	4	c294cd421f277992b56ae9c40b8f3948e33148fe
ToppCell	10x5'-bone_marrow-Myeloid_Dendritic-pDC\|bone_marrow / Manually curated celltypes from each tissue	CUX2 COBL IRF4 CDHR5	3.69e-04	184	82	4	2817d530863e85dfdcd143b7a3dc5fc58a9cd98b
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1-D175\|Adult / Lineage, Cell type, age group and donor	CARMIL1 COBL NCKAP5 NRG3	3.77e-04	185	82	4	32b4e68e551d435a732f253f6ad83408c759a642
ToppCell	control-Myeloid-pDC\|control / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	CUX2 AXL COBL IRF4	3.85e-04	186	82	4	fe31e9cf4575ee40b50489593c51d8c36c3cc532
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	COBL NCKAP5 NRG3 VWCE	3.85e-04	186	82	4	f28d72b47624b69a580b4429e2be560a26898591
ToppCell	Smart-seq2-spleen_(Smart-seq2)-lymphocytic-innate_lymphocytic-mature_NK_T_cell\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	PTPN12 SYNE2 NR4A2 MEX3C	3.92e-04	187	82	4	6981b856187a2e689260ecb7d0a1193a374ee9b9
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1\|Adult / Lineage, Cell type, age group and donor	CARMIL1 COBL NCKAP5 NRG3	3.92e-04	187	82	4	77f78aec946bc6bd85c29aee9ca978ce49f853a3
ToppCell	Control-Epithelial-ATI\|Epithelial / Disease state, Lineage and Cell class	ATOH8 NCKAP5 NRG3 PDLIM2	3.92e-04	187	82	4	3a032432f780525f4f4c2a358897d9989b1ecae7
ToppCell	droplet-Tongue-nan\|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SYNE2 NR4A2 ANKRD11 SRRM2	4.00e-04	188	82	4	d62cc37e86b7b186e53aeb7f421c4e5ee28f23bd
ToppCell	Adult-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)\|Adult / Lineage, Cell type, age group and donor	RIN2 FAM110D OBSCN NRG3	4.00e-04	188	82	4	e5cad03f4a64147fe8174e7f614cf45233ffb9b7
ToppCell	IPF-Endothelial-VE_Capillary_A\|World / Disease state, Lineage and Cell class	NCKAP5 NRG3 SHROOM2 TNFRSF4	4.09e-04	189	82	4	ea3aa3ef38f1d405bb527ae383cd12c551a3dd6f
ToppCell	RA-10._Endothelium_II\|RA / Chamber and Cluster_Paper	PTPN12 RIN2 NRG3 SHROOM2	4.09e-04	189	82	4	c81787a8c662db5d7814c583dd64562857629e81
ToppCell	COPD-Epithelial-ATI\|Epithelial / Disease state, Lineage and Cell class	ATOH8 NCKAP5 NRG3 PDLIM2	4.09e-04	189	82	4	14e8e57e4db336fbef005270647983b4edf407c0
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	CABP1 CUX2 CRACDL CARMIL1	4.09e-04	189	82	4	c3df0e3c50af8f1cfb4d790e668bd7f42b276992
ToppCell	BAL-Control-Lymphocyte-B-B_cell\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SYNE2 NR4A2 IRF4 CLBA1	4.17e-04	190	82	4	da7341a8a423e5fe4d8e733d8e50c10a3318ac1c
ToppCell	Globus_pallidus-Neuronal\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	CARMIL2 CELSR3 NRG3 KIFC2	4.17e-04	190	82	4	416de85d8841dac883faa6f5339b2fb461a09e82
ToppCell	BAL-Control-Lymphocyte-B-B_cell-B_cell\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SYNE2 NR4A2 IRF4 CLBA1	4.17e-04	190	82	4	42312f7d79fe889397d32910b625793e2535cc26
ToppCell	Children_(3_yrs)-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	RIN2 OBSCN NRG3 SHROOM2	4.17e-04	190	82	4	0a351609a72fd638c84b2435782e312ee6a33aac
ToppCell	BAL-Control-Lymphocyte-B-B_cell-B_cell-B_activate-7\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SYNE2 NR4A2 IRF4 CLBA1	4.17e-04	190	82	4	682418a7a2096743112eae3790d40e7e600612c0
ToppCell	droplet-Kidney-KIDNEY-1m-Epithelial-Stroma____kidney_mesangial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CABP1 AXL ATOH8 NR4A2	4.25e-04	191	82	4	8597a8af294f24496c317d995f07eb5dcc25c13c
ToppCell	mild_COVID-19-gd_T\|mild_COVID-19 / disease group, cell group and cell class (v2)	SYNE2 NR4A2 ALK MIR9-1HG	4.25e-04	191	82	4	0e43c097b92aaa831811d60e033262999e79dcd7
ToppCell	RA-09._Endothelium_I\|World / Chamber and Cluster_Paper	CRACDL RIN2 SYNE2 NRG3	4.25e-04	191	82	4	c8a0c2af119bc34a8f694a7d30642f28002c84b9
ToppCell	Posterior_cortex-Neuronal-Excitatory-eN1(Slc17a7)-eN1_1-Calb1-Excitatory_Neuron.Slc17a7-Slc17a6.Calb1-Rorb-Il1rapl2_(Layer_5b)\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	CER1 MYO15A USH2A	4.33e-04	80	82	3	402aba070f0728ebda9db7a8fa85441533755ff4
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c03-ITGA4\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	SYNE2 TNRC6C DDX24 TNFRSF4	4.34e-04	192	82	4	7ab626a516b07d899175ff12f1c8257688324e4b
ToppCell	RA-09._Endothelium_I\|RA / Chamber and Cluster_Paper	CRACDL RIN2 SYNE2 NRG3	4.34e-04	192	82	4	8a1b1c3e83a68ad74f8f4eb00455c9e41aa57cfc
ToppCell	renal_cortex_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE2 ANKRD11 NCKAP5 MED13L	4.34e-04	192	82	4	e8cc4d08fcfceeab75a02558817e4ccd7dbafe3a
Drug	Meticrane [1084-65-7]; Up 200; 14.6uM; PC3; HT_HG-U133A	OGFR NR4A2 COBL SRRM2 SHROOM2 SYDE1 PML	5.58e-06	192	81	7	1792_UP
Drug	Fusaric acid [536-69-6]; Up 200; 22.4uM; MCF7; HT_HG-U133A	PRR36 RIN2 MARK4 NR4A2 SRF PPP1R37 CLBA1	5.97e-06	194	81	7	3245_UP
Drug	Moricizine hydrochloride [31883-05-3]; Up 200; 8.6uM; HL60; HT_HG-U133A	ADAMTS7 NR4A2 FRS2 PDLIM2 MIR9-1HG ARHGAP33 PML	5.97e-06	194	81	7	2959_UP
Drug	Netilmicin sulfate [56931-57-2]; Up 200; 2.8uM; MCF7; HT_HG-U133A	ADAMTS7 KCND3 OGFR CDHR5 GNAS HSF4 MN1	6.61e-06	197	81	7	3524_UP
Drug	Diperodon hydrochloride [537-12-2]; Down 200; 9.2uM; PC3; HT_HG-U133A	OGFR MARK4 DVL2 NR4A2 SRRM2 ARHGAP33 PML	6.83e-06	198	81	7	4498_DN
Drug	Procyclidine hydrochloride [1508-76-5]; Up 200; 12.4uM; PC3; HT_HG-U133A	KCND3 MARK4 HSF4 ARHGAP33 CLBA1 PML TNFRSF4	6.83e-06	198	81	7	4233_UP
Drug	Ritodrine hydrochloride [23239-51-2]; Up 200; 12.4uM; MCF7; HT_HG-U133A	CUX2 MARK4 SYDE1 MIR9-1HG ARHGAP33 CLBA1 PML	7.06e-06	199	81	7	2635_UP
Drug	LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A	CELSR3 RIN2 MARK4 NR4A2 CLBA1 PML	4.74e-05	182	81	6	1661_UP
Drug	Securinine [5610-40-2]; Up 200; 18.4uM; MCF7; HT_HG-U133A	CABP1 MARK4 SRF GNAS MED13L MN1	5.35e-05	186	81	6	6831_UP
Drug	Forskolin, from Coleus forskohlii; Up 200; 0.5uM; PC3; HT_HG-U133A	CELSR3 MCM9 MARK4 NR4A2 COBL PML	5.68e-05	188	81	6	7104_UP
Drug	Benfluorex hydrochloride [23642-66-2]; Up 200; 10.4uM; MCF7; HT_HG-U133A	KCND3 OGFR MARK4 DVL2 NR4A2 MYO15A	6.76e-05	194	81	6	2621_UP
Drug	valinomycin; Down 200; 0.1uM; PC3; HT_HG-U133A	NR4A2 COBL SHROOM2 MN1 ARHGAP33 PML	6.96e-05	195	81	6	5911_DN
Drug	Flumethasone [2135-17-3]; Up 200; 9.8uM; PC3; HT_HG-U133A	KCND3 FRS2 SRF IRF4 SYDE1 PML	6.96e-05	195	81	6	4272_UP
Drug	Boldine [476-70-0]; Down 200; 12.2uM; MCF7; HT_HG-U133A	CELSR3 MARK4 DVL2 IRF4 PDLIM2 PML	7.16e-05	196	81	6	4122_DN
Drug	Torsemide [56211-40-6]; Down 200; 11.4uM; MCF7; HT_HG-U133A	OGFR MARK4 DVL2 FRS2 SRRM2 SYDE1	7.16e-05	196	81	6	3517_DN
Drug	Heptaminol hydrochloride [543-15-7]; Down 200; 22uM; MCF7; HT_HG-U133A	PRR4 OGFR RIN2 NR4A2 FRS2 ARHGAP33	7.16e-05	196	81	6	6015_DN
Drug	Prostaglandin E1; Down 200; 10uM; PC3; HT_HG-U133A	KCND3 AXL TRIOBP MYO15A MN1 PML	7.16e-05	196	81	6	6571_DN
Drug	Chloramphenicol [56-75-7]; Up 200; 12.4uM; MCF7; HT_HG-U133A	PRR4 MIA3 MARK4 NR4A2 ALK ARHGAP33	7.16e-05	196	81	6	5466_UP
Drug	Azathioprine [446-86-6]; Up 200; 14.4uM; MCF7; HT_HG-U133A	PRR4 MARK4 NR4A2 ALK ARHGAP33 PML	7.36e-05	197	81	6	1528_UP
Drug	Cyclacillin [3485-14-1]; Down 200; 11.8uM; PC3; HT_HG-U133A	DVL2 SRF GNAS ALK SYDE1 PML	7.36e-05	197	81	6	3800_DN
Drug	Guanadrel sulfate [22195-34-2]; Down 200; 7.6uM; MCF7; HT_HG-U133A	PRR36 FRS2 PPP1R37 GNAS SYDE1 PML	7.36e-05	197	81	6	4720_DN
Drug	Austricine [10180-88-8]; Up 200; 14.2uM; MCF7; HT_HG-U133A	PTPN12 OGFR HSF4 ALK SYDE1 PML	7.36e-05	197	81	6	4797_UP
Drug	Rauwolscine hydrochloride [6211-32-1]; Up 200; 10.2uM; MCF7; HT_HG-U133A	KCND3 OGFR RIN2 MARK4 MYO15A PML	7.36e-05	197	81	6	6274_UP
Drug	alpha-Santonin [481-06-1]; Down 200; 16.2uM; MCF7; HT_HG-U133A	PRR4 MARK4 DVL2 SRF GNAS PML	7.36e-05	197	81	6	3877_DN
Drug	Pseudopelletierine hydrochloride [6164-62-1]; Up 200; 21uM; MCF7; HT_HG-U133A	PRR36 SRRM2 ALK MIR9-1HG ARHGAP33 CLBA1	7.36e-05	197	81	6	2766_UP
Drug	Prilocaine hydrochloride [1786-81-8]; Up 200; 15.6uM; MCF7; HT_HG-U133A	PRR36 KCND3 MARK4 MIR9-1HG CLBA1 PML	7.57e-05	198	81	6	3624_UP
Drug	Cyproterone acetate [427-51-0]; Up 200; 9.6uM; PC3; HT_HG-U133A	NR4A2 IRF4 SRRM2 ALK SYDE1 PML	7.57e-05	198	81	6	4470_UP
Drug	Methacycline hydrochloride [3963-95-9]; Up 200; 8.4uM; HL60; HT_HG-U133A	CABP1 CELSR3 OGFR SRRM2 MIR9-1HG PML	7.57e-05	198	81	6	2901_UP
Drug	Hydroquinine hydrobromide hydrate [304695-81-6]; Up 200; 9.4uM; PC3; HT_HG-U133A	KCND3 OGFR DVL2 SRF ARHGAP33 PML	7.57e-05	198	81	6	5789_UP
Drug	Paroxetine maleate [64006-44-6]; Down 200; 1uM; MCF7; HT_HG-U133A	MARK4 FRS2 IRF4 GNAS SYDE1 PML	7.57e-05	198	81	6	4378_DN
Drug	Phenformin hydrochloride [834-28-6]; Up 200; 16.6uM; MCF7; HT_HG-U133A	OGFR MARK4 SRF PPP1R37 CLBA1 PML	7.57e-05	198	81	6	3622_UP
Drug	Indoprofen [31842-01-0]; Down 200; 14.2uM; MCF7; HT_HG-U133A	MIA3 OGFR MARK4 SRF TRIOBP SRRM2	7.78e-05	199	81	6	3345_DN
Drug	Conessine [546-06-5]; Up 200; 11.2uM; MCF7; HT_HG-U133A	MARK4 DVL2 SRF IRF4 GNAS PML	7.78e-05	199	81	6	4777_UP
Drug	Diphenylpyraline hydrochloride [132-18-3]; Down 200; 12.6uM; MCF7; HT_HG-U133A	OGFR SRF GNAS ARHGAP33 CLBA1 PML	7.78e-05	199	81	6	4765_DN
Drug	Ganciclovir [82410-32-0]; Up 200; 15.6uM; HL60; HT_HG-U133A	CUX2 FAM110D PPP1R37 IRF4 CDHR5 ARHGAP33	8.00e-05	200	81	6	3030_UP
Drug	Methylergometrine maleate [113-42-8]; Up 200; 8.8uM; MCF7; HT_HG-U133A	MIA3 KCND3 NR4A2 SRF IRF4 MYO15A	8.00e-05	200	81	6	3222_UP
Drug	sibutramine	KCND3 GNAS PDLIM2	3.90e-04	40	81	3	CID000005210
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	RIN2 TRIOBP GNAS SRRM2 SYDE1	4.05e-04	175	81	5	7387_DN
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A	RIN2 MCM9 TRIOBP SRRM2 MEX3C	4.72e-04	181	81	5	7077_DN
Drug	(+)-Isoproterenol (+)-bitartrate salt [14638-70-1]; Up 200; 11uM; PC3; HT_HG-U133A	ADAMTS7 NR4A2 COBL SYDE1 PML	4.84e-04	182	81	5	6663_UP
Drug	Chloropyramine hydrochloride [6170-42-9]; Up 200; 12.2uM; PC3; HT_HG-U133A	KCND3 SRF ALK SYDE1 PML	5.48e-04	187	81	5	4589_UP
Drug	0297417-0002B [362658-29-5]; Up 200; 10uM; MCF7; HT_HG-U133A	OGFR RIN2 NR4A2 MED13L PML	5.48e-04	187	81	5	6902_UP
Drug	Methotrexate [59-05-2]; Down 200; 8.8uM; PC3; HT_HG-U133A	OGFR MCM9 MN1 PDLIM2 PML	5.89e-04	190	81	5	6318_DN
Drug	Labetalol hydrochloride [32780-64-6]; Up 200; 11uM; HL60; HG-U133A	MARK4 NR4A2 PDLIM2 SYDE1 ARHGAP33	5.89e-04	190	81	5	1550_UP
Drug	Tolbutamide [64-77-7]; Down 200; 14.8uM; MCF7; HT_HG-U133A	MIA3 SRF SRRM2 PDLIM2 PML	5.89e-04	190	81	5	4362_DN
Drug	geldanamycin; Down 200; 1uM; PC3; HT_HG-U133A	CHAF1B PTPN12 OGFR DVL2 PML	5.89e-04	190	81	5	4452_DN
Drug	Chlorprothixene hydrochloride [6469-93-8]; Up 200; 11.4uM; MCF7; HT_HG-U133A	PRR4 NR4A2 MYO15A SYDE1 PML	6.03e-04	191	81	5	2627_UP
Drug	DNA-PK Inhibitor III; Up 200; 1uM; PC3; HT_HG-U133A	OGFR MCM9 DVL2 SYDE1 PML	6.17e-04	192	81	5	7548_UP
Drug	LY 294002; Down 200; 10uM; PC3; HT_HG-U133A	OGFR COBL SRRM2 PDLIM2 PML	6.32e-04	193	81	5	4460_DN
Drug	Etofenamate [30544-47-9]; Up 200; 10.8uM; PC3; HT_HG-U133A	CELSR3 DVL2 NR4A2 ALK ARHGAP33	6.32e-04	193	81	5	3989_UP
Drug	PF-01378883-00 [351320-41-7]; Up 200; 10uM; PC3; HT_HG-U133A	CABP1 ADAMTS7 MYO15A ALK PML	6.47e-04	194	81	5	6368_UP
Drug	Strophanthidin [66-28-4]; Down 200; 9.8uM; PC3; HT_HG-U133A	MIA3 OGFR RIN2 COBL SHROOM2	6.47e-04	194	81	5	5826_DN
Drug	Hydroxyzine dihydrochloride [2192-20-3]; Down 200; 9uM; PC3; HT_HG-U133A	CELSR3 MARK4 DVL2 ARHGAP33 PML	6.47e-04	194	81	5	6660_DN
Drug	Clobetasol propionate [25122-46-7]; Up 200; 8.6uM; MCF7; HT_HG-U133A	CELSR3 PRR36 MARK4 NR4A2 SRRM2	6.47e-04	194	81	5	6835_UP
Drug	5279552; Up 200; 22uM; MCF7; HT_HG-U133A_EA	CELSR3 OGFR RIN2 TRIOBP CEP131	6.47e-04	194	81	5	843_UP
Drug	Acyclovir [59277-89-3]; Down 200; 17.8uM; MCF7; HT_HG-U133A	OGFR MARK4 DVL2 ALK PML	6.47e-04	194	81	5	5278_DN
Drug	(1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Up 200; 11.8uM; PC3; HT_HG-U133A	NR4A2 COBL ARHGAP33 CLBA1 PML	6.47e-04	194	81	5	4546_UP
Drug	Skimmianine [83-95-4]; Up 200; 15.4uM; MCF7; HT_HG-U133A	KCND3 OGFR MARK4 IRF4 PML	6.47e-04	194	81	5	6242_UP
Drug	Cyclacillin [3485-14-1]; Down 200; 11.8uM; MCF7; HT_HG-U133A	PRR4 OGFR MARK4 ALK ARHGAP33	6.62e-04	195	81	5	4358_DN
Drug	Hesperidin [520-26-3]; Up 200; 6.6uM; MCF7; HT_HG-U133A	PTPN12 CELSR3 OGFR MARK4 PML	6.62e-04	195	81	5	5313_UP
Drug	Bumetanide [28395-03-1]; Down 200; 11uM; HL60; HT_HG-U133A	OGFR MARK4 DVL2 NR4A2 PML	6.62e-04	195	81	5	2409_DN
Drug	Phentolamine hydrochloride [73-05-2]; Up 200; 12.6uM; MCF7; HT_HG-U133A	KCND3 NR4A2 SRF MIR9-1HG CLBA1	6.62e-04	195	81	5	3860_UP
Drug	Fluspirilen [1841-19-6]; Up 200; 8.4uM; PC3; HT_HG-U133A	KCND3 OGFR NR4A2 IRF4 SYDE1	6.62e-04	195	81	5	6662_UP
Drug	Thiamphenicol [15318-45-3]; Up 200; 11.2uM; MCF7; HT_HG-U133A	PRR4 CUX2 OGFR MARK4 NR4A2	6.62e-04	195	81	5	7033_UP
Drug	Tacrine hydrochloride hydrate [1684-40-8]; Down 200; 15.8uM; PC3; HT_HG-U133A	CELSR3 MARK4 NR4A2 SYDE1 PML	6.62e-04	195	81	5	6698_DN
Drug	NS-398; Down 200; 10uM; PC3; HT_HG-U133A	OGFR FRS2 PPP1R37 GNAS PML	6.62e-04	195	81	5	6892_DN
Drug	Palmatine chloride [3486-67-7]; Up 200; 10.4uM; MCF7; HT_HG-U133A	RIN2 ALK MIR9-1HG ARHGAP33 PML	6.62e-04	195	81	5	2795_UP
Drug	Thiamphenicol [15318-45-3]; Down 200; 11.2uM; HL60; HT_HG-U133A	OGFR MARK4 NR4A2 PDLIM2 PML	6.62e-04	195	81	5	1867_DN
Drug	Isosorbide dinitrate [87-33-2]; Down 200; 17uM; MCF7; HT_HG-U133A	RIN2 MARK4 SRF SRRM2 PML	6.62e-04	195	81	5	4742_DN
Drug	Furazolidone [67-45-8]; Down 200; 17.8uM; MCF7; HT_HG-U133A	MARK4 DVL2 TRIOBP SRRM2 ALK	6.62e-04	195	81	5	3358_DN
Drug	Trimethadione [127-48-0]; Down 200; 28uM; MCF7; HT_HG-U133A	PRR36 MARK4 SYDE1 CLBA1 PML	6.78e-04	196	81	5	4165_DN
Drug	estradiol; Up 200; 0.01uM; PC3; HT_HG-U133A	CABP1 OGFR PPP1R37 IRF4 GNAS	6.78e-04	196	81	5	5910_UP
Drug	Megestrol acetate [595-33-5]; Up 200; 10.4uM; PC3; HT_HG-U133A	PTPN12 KCND3 OGFR COBL SYDE1	6.78e-04	196	81	5	6667_UP
Drug	PNU-0230031 [267429-39-0]; Up 200; 10uM; PC3; HT_HG-U133A	PRR36 FAM110D DVL2 COBL PML	6.78e-04	196	81	5	3732_UP
Drug	Isosorbide dinitrate [87-33-2]; Up 200; 17uM; PC3; HT_HG-U133A	PPP1R37 IRF4 ALK SYDE1 CLBA1	6.78e-04	196	81	5	3720_UP
Drug	Foliosidine [2520-38-9]; Down 200; 13uM; PC3; HT_HG-U133A	PRR4 OGFR ALK SYDE1 PML	6.78e-04	196	81	5	3739_DN
Drug	Apramycin [37321-09-8]; Up 200; 7.4uM; HL60; HT_HG-U133A	OGFR SRF SRRM2 SYDE1 PML	6.78e-04	196	81	5	2914_UP
Drug	Acacetin [480-44-4]; Up 200; 14uM; MCF7; HT_HG-U133A	SRF PPP1R37 MED13L SRRM2 MIR9-1HG	6.78e-04	196	81	5	3849_UP
Drug	Citalopram hydrobromide [59729-32-7]; Up 200; 1uM; MCF7; HT_HG-U133A	CUX2 FAM110D MARK4 NR4A2 PML	6.78e-04	196	81	5	3903_UP
Drug	CP-863187 [668981-07-5]; Up 200; 10uM; PC3; HT_HG-U133A	MIA3 AXL COBL SHROOM2 PML	6.78e-04	196	81	5	7558_UP
Drug	Ofloxacin [82419-36-1]; Down 200; 11uM; PC3; HT_HG-U133A	OGFR MARK4 NR4A2 COBL SYDE1	6.78e-04	196	81	5	3673_DN
Drug	Prilocaine hydrochloride [1786-81-8]; Up 200; 15.6uM; HL60; HT_HG-U133A	MARK4 DVL2 PDLIM2 MIR9-1HG PML	6.78e-04	196	81	5	2352_UP
Drug	Napelline [5008-52-6]; Up 200; 11.2uM; MCF7; HT_HG-U133A	MIA3 SRF TLE6 ALK PML	6.78e-04	196	81	5	6084_UP
Drug	Beclomethasone dipropionate [5534-09-8]; Down 200; 7.6uM; PC3; HT_HG-U133A	CELSR3 NR4A2 PDLIM2 ALK MIR9-1HG	6.78e-04	196	81	5	4580_DN
Drug	Phenformin hydrochloride [834-28-6]; Down 200; 16.6uM; MCF7; HT_HG-U133A	NR4A2 SRRM2 MIR9-1HG CLBA1 PML	6.78e-04	196	81	5	4747_DN
Drug	Indomethacin [53-86-1]; Down 200; 11.2uM; HL60; HT_HG-U133A	PRR4 OGFR MARK4 ALK SYDE1	6.78e-04	196	81	5	2377_DN
Drug	Progesterone [57-83-0]; Up 200; 12.8uM; PC3; HT_HG-U133A	ADAMTS7 KCND3 FAM110D SRF SYDE1	6.78e-04	196	81	5	6646_UP
Drug	Gossypol [303-45-7]; Down 200; 7.8uM; PC3; HT_HG-U133A	PRR4 OGFR MARK4 DVL2 PML	6.78e-04	196	81	5	4296_DN
Drug	PHA-00851261E [724719-49-7]; Down 200; 1uM; MCF7; HT_HG-U133A	PRR36 MARK4 SRF SYDE1 PML	6.78e-04	196	81	5	3857_DN
Drug	Deptropine citrate [2169-75-7]; Up 200; 7.6uM; HL60; HT_HG-U133A	CELSR3 KCND3 IRF4 SRRM2 ALK	6.78e-04	196	81	5	3144_UP
Drug	2-propylpentanoic acid; Down 200; 50uM; PC3; HT_HG-U133A	NR4A2 FRS2 COBL MN1 ARHGAP33	6.78e-04	196	81	5	4446_DN
Drug	genistein; Up 200; 10uM; HL60; HT_HG-U133A	ADAMTS7 DVL2 NR4A2 USH2A PML	6.78e-04	196	81	5	6194_UP
Drug	Methylhydantoin-5-(D) [55147-68-7]; Up 200; 35uM; PC3; HT_HG-U133A	CELSR3 OGFR COBL ARHGAP33 CLBA1	6.78e-04	196	81	5	3994_UP
Drug	Epicatechin-(-) [154-23-4]; Down 200; 13.8uM; HL60; HT_HG-U133A	CELSR3 AXL OGFR MARK4 PDLIM2	6.78e-04	196	81	5	2160_DN
Drug	9-deoxy-9-methylene-16,16-dimethyl Prostaglandin E2; Up 200; 10uM; MCF7; HT_HG-U133A	CELSR3 PRR36 SRF TLE6 SRRM2	6.93e-04	197	81	5	7500_UP
Drug	Ethosuximide [77-67-8]; Down 200; 28.4uM; PC3; HT_HG-U133A	SYNE2 COBL CEP131 GNAS SYDE1	6.93e-04	197	81	5	2116_DN
Drug	Nizatidine [76963-41-2]; Up 200; 12uM; MCF7; HT_HG-U133A	NR4A2 IRF4 HSF4 ALK PML	6.93e-04	197	81	5	3385_UP
Drug	Pheniramine maleate [132-20-7]; Up 200; 11.2uM; PC3; HT_HG-U133A	PRR36 KCND3 OGFR MYO15A SRRM2	6.93e-04	197	81	5	4012_UP
Drug	Gelsemine [509-15-9]; Down 200; 12.4uM; MCF7; HT_HG-U133A	MARK4 DVL2 TRIOBP CLBA1 PML	6.93e-04	197	81	5	4177_DN
Drug	Deltaline [6836-11-9]; Down 200; 7.8uM; HL60; HT_HG-U133A	PTPN12 OGFR MARK4 NR4A2 CEP131	6.93e-04	197	81	5	2171_DN
Disease	hearing impairment	TRIOBP MYO15A USH2A MN1	1.35e-04	98	78	4	C1384666
Disease	immature platelet count	GFI1B CARMIL1 MARK4 GNAS	1.83e-04	106	78	4	EFO_0803544
Disease	immature platelet fraction	GFI1B CARMIL1 MARK4 GNAS	2.42e-04	114	78	4	EFO_0009187
Disease	creatinine measurement	CHAF1B CUX2 PTPN12 CELSR3 ADAMTS7 OGFR WBP1L OBSCN ANKRD11 GNAS	2.87e-04	995	78	10	EFO_0004518
Disease	Arthritis, Psoriatic	NR4A2 FBXL19	6.15e-04	14	78	2	C0003872
Disease	sphingomyelin measurement	CRACDL SYNE2 ANKRD11 TNRC6C USH2A	8.63e-04	278	78	5	EFO_0010118
Disease	Alzheimer disease, psychotic symptoms	CHAF1B TNRC6C	9.14e-04	17	78	2	EFO_0005940, MONDO_0004975
Disease	nucleotide measurement	CARMIL1 SYNE2 ALK	9.67e-04	73	78	3	EFO_0010513
Disease	skin sensitivity to sun	ANKRD11 IRF4	1.15e-03	19	78	2	EFO_0004795
Disease	hair color	SYNE2 ANKRD11 IRF4 MED13L TNFRSF4	1.42e-03	311	78	5	EFO_0003924
Disease	basal cell carcinoma	SCAF1 ANKRD11 IRF4 MYO15A	1.61e-03	189	78	4	EFO_0004193
Disease	basophil count	GFI1B CUX2 WBP1L MARK4 TRIOBP TSGA10IP	1.77e-03	483	78	6	EFO_0005090
Disease	nevus count, cutaneous melanoma	MIA3 SYNE2 MED13L	1.83e-03	91	78	3	EFO_0000389, EFO_0004632
Disease	PR interval	UBXN11 KCND3 CARMIL1 SYNE2 OBSCN NCKAP5	2.00e-03	495	78	6	EFO_0004462
Disease	HbA1c measurement	GFI1B CUX2 ADAMTS7 AXL CARMIL1 TNRC6C MYO15A	2.06e-03	675	78	7	EFO_0004541
Disease	monocyte count	PIK3AP1 GFI1B UBXN11 ARHGAP23 CARMIL1 WBP1L MARK4 MED13L MN1 MIR9-1HG	2.46e-03	1320	78	10	EFO_0005091

Protein segments in the cluster

Peptide	Gene	Start	Entry
RESPRPPDPATDSAS	BDP1	31	A6H8Y1
ASPRPDQSRPTGVPT	ANKRD11	1691	Q6UB99
SPERSPPSPATDQRG	CARMIL2	1416	Q6F5E8
ESLSETPGPSSPRQP	ARHGEF5	1116	Q12774
DPSSPGTTPPQARQA	CHAF1B	426	Q13112
PSRDSDSEPFPPGTQ	CER1	96	O95813
STTSEVPRPPEPSQG	CDHR5	476	Q9HBB8
PGASQASPTEPRSSP	CUX2	971	O14529
RSRSPGPPQVDGTPT	PIK3AP1	756	Q6ZUJ8
PATPQSSGDPSSRRP	CABP1	106	Q9NZU7
TTDSSRAPSSPRPPG	MIR9-1HG	51	Q13536
PPERTSGIGDSRPPS	DVL2	121	O14641
RDSSLEPGTPSFPTP	ADAMTS7	1306	Q9UKP4
TRPPPAQSPTGSDTR	ANO8	1006	Q9HCE9
SAEGPAVPSPSPQRE	FBXL19	291	Q6PCT2
TPIPNGPRVETPDSS	INSYN1	146	Q2T9L4
ESTVRPAPPTRPGES	ATOH8	176	Q96SQ7
PQSFPEVPSPDRGSQ	NRG3	451	P56975
PAEATSSPTSPERPR	MMTAG2	211	Q9BU76
SIPTPPALTPEGESR	KCND3	616	Q9UK17
PPTLSPQPRGQETES	MED13L	556	Q71F56
PQPRGQETESLDPPS	MED13L	561	Q71F56
SAPSPPPRSRSGSES	LYSMD2	21	Q8IV50
SETPPAPSSREASRP	NELFA	341	Q9H3P2
APSSREASRPPEEPS	NELFA	346	Q9H3P2
PESQAPGVPTEPSIR	IRF4	226	Q15306
SSSGTEDTPRRPPEP	MYO15A	2426	Q9UKN7
SRPQDGDSPLSDSPP	GFI1B	86	Q5VTD9
SSEPEAGPSQPPVRQ	FAM214B	11	Q7L5A3
SFPRDPRTPQDPSSV	GNL1	256	P36915
VSPGSPPSSPRSRDA	RGL3	551	Q3MIN7
PERIGTEPSTAPAPS	CRACDL	476	Q6NV74
GDRSPPGSPSTPTEQ	PPP1R37	541	O75864
EVGRAPTRSSPEPTP	OBSCN	7256	Q5VST9
RAPPQPSGSRPDTVT	ARHGAP33	616	O14559
ELEVPRTPRTPTTPG	FRS2	126	Q8WU20
GRPSESSARGPPSTP	COBL	781	O75128
NTSQPDPSRPGTERT	GDF5-AS1	126	Q5U4N7
SRAPPSTQEPQSPRE	GNAS	176	O95467
EPSSSRPSRIDPQEP	FCRL3	621	Q96P31
PEDSPSPEGTRLSPS	HSF4	266	Q9ULV5
ENSSGTPRVPPASPS	MARK4	531	Q96L34
PPSNTEAPPGETRTE	DDX24	266	Q9GZR7
PRTASRPDDIPDSPS	CARMIL1	1276	Q5VZK9
PASGSAPRESRTAPE	CELSR3	256	Q9NYQ7
QVSQPRSGSPRPTEP	CEP131	81	Q9UPN4
RPPSPDGSTSQEESP	KIFC2	151	Q96AC6
RREQPPTEPGPQSAS	OGFR	391	Q9NZT2
RTPTSSSGAPPPDEI	MN1	1136	Q10571
RGERGPSSPPTTTAP	MCM9	1081	Q9NXL9
TQVPSPPSRGSPSNE	NR4A2	246	P43354
RDPPNRVPPTTEGTR	SYDE1	501	Q6ZW31
EHSPQRPPRTEPTGS	TSGA10IP	526	Q3SY00
EVTTRPSRPAGVQPP	USH2A	2716	O75445
PPSADDSRVIGSPTP	TNRC6C	1661	Q9HCJ0
VNPPSEASPTRDRSP	SRRM2	391	Q9UQ35
EGDRNVPPVPPASST	SYNE2	6471	Q8WXH0
PSGSRDEPPPASQST	MIA3	1881	Q5JRA6
EPGSDRRSCPPTPTD	NCKAP5	1406	O14513
EGRQPSPSPSPTERA	PML	31	P29590
RRDTSGPTPGTPSPA	PRR36	161	Q9H6K5
GSQPSTPRLSPTFPE	MEX3C	536	Q5U5Q3
PEESQNSDTPPRPDR	PTPN12	511	Q05209
RSPGDVPQSPSDVSP	SIMC1	291	Q8NDZ2
RRPESSPEDSATRPP	SHROOM2	596	Q13796
TEERARPAPSRDPSP	NOM1	126	Q5C9Z4
REPASAESPQAPTGP	IQANK1	46	A8MXQ7
PRDAAPSSPASTERP	FAM110D	116	Q8TAY7
PSPGPRSSRPSMDSE	PDLIM2	196	Q96JY6
PTQGDRPQTSSPSRP	TRIOBP	941	Q9H2D6
SPDSPPRSDPTTDQR	SRF	221	P11831
PGENSPRQTPIFDPT	ALK	666	Q9UM73
LEGPTEPQPPRTTSA	CLBA1	101	Q96F83
GDCTRAPPPSSESRP	RIN2	406	Q8WYP3
GDESPRPDAQPTQPT	SCAF1	316	Q9H7N4
PAPGTPPQVDSTRAD	SCAF1	331	Q9H7N4
SSEPRTPRAFPEPGS	ARHGAP23	261	Q9P227
PRRPQTPTPSEQDAD	ZSCAN1	11	Q8NBB4
QPPPVTPERSFSASG	VWCE	866	Q96DN2
STTPSPAQPADRGSP	AXL	871	P30530
SGSRRASPPGTPTPE	REM2	21	Q8IYK8
PEPPRTAPEVGSNSQ	PRR33	46	A8MZF0
EDSSQRPDQGPQRPP	PRR4	36	Q16378
PRTSQGPSTRPVEVP	TNFRSF4	196	P43489
SSTPSNTAPRIPEPG	nan	21	Q8IYB0
RSSTRPPSIADPDPS	WBP1L	166	Q9NX94
RPPEASSSPPEGSQD	TLE6	211	Q9H808
ERERSQESPNTPAPP	UBXN11	381	Q5T124